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Abstract
Telomerase, a ribonucleoprotein important to neoplastic immortality, is up-regulated in approximately 85% of can-
cers, including leukemias. In this study, 9cUAB30, a novel retinoic acid, resulted in differentiation of HL60 leukemia
cells as indicated by morphologic changes characteristic of granulocytes. It also caused a down-regulation of
hTERT gene expression and a decrease in telomerase activity. Telomerase inhibition was followed by loss of pro-
liferative capacity, induction of apoptosis, and partial differentiation. These findings demonstrate the effectiveness
of 9cUAB30 at inhibiting telomerase activity by down-regulating hTERT gene expression in human leukemic cells.
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Introduction
The ability to replicate indefinitely is a characteristic of both stem
and cancer cells, but not normal somatic cells. This proliferative
immortality is achieved through the activity of the ribonucleoprotein
telomerase. Approximately 85% of cancers display an aberrant in-
crease in telomerase activity, and as a result, anticancer therapeutics
aimed at exploiting this cancer-specific activation of telomerase ex-
pression promise a high degree of translational potential [1]. Telo-
merase activity is minimal, almost undetectable, in most normal
tissues [2]; however, leukemic cells display much higher levels of telo-
merase activity [3,4]. Telomerase functions by adding hexameric
repeats of DNA nucleotides to the 5′ ends of linear chromosomes,
compensating for the slow erosion of DNA that results from the
inability of DNA polymerase II to effectively replicate the end of
the DNA strand. The strong correlation between hTERT mRNA
expression and telomerase activity has made inhibition of hTERT
expression important to preventing cellular immortalization.
Retinoids such as all-trans retinoic acid (ATRA) and 9-cis retinoic
acid are derivatives of vitamin A that play a pivotal role in a diverse
group of biologic processes including, but not limited to, cellular
proliferation, differentiation, apoptosis, and development [5]. Reti-
noic acids (RAs) have been studied intensively for their anticancer
effects, which are exerted through a wide range of mechanisms. In-
hibition of telomerase in leukemic cells using RAs has been shown
to slow proliferation and induce a differentiation to a more benign
phenotype [6]. Leukemias are not the only cancer in which retinoids
have been used to inhibit telomerase activity, as RAs have been
shown to effectively treat or prevent breast, cervical, neural, and
many of the subtypes of hematological cancers [7–10].
Acute promyelocytic leukemias (APLs) respond readily to ATRA,
which induces differentiation and apoptosis [11]. In HL60 cells,
it has been shown that ATRA induces a repression of hTERT ex-
pression resulting in telomere shortening and cell death [3]. Despite
these findings, the negative effect of ATRA treatment on normal
healthy cells has hindered the development of ATRA-based anticancer
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therapies. As a result, much focus has been placed on the develop-
ment of synthetic retinoids that display the same anticancer proper-
ties but lack the off-target effects of ATRA and other RAs. Retinoids
freely pass through the cell and nuclear membrane, where once inside
the nucleus, they bind to two classes of nuclear receptors, retinoic
acid receptors (RARs) and retinoid X receptors (RXRs) in addition
to cytoplasmic binding proteins. Once bound, the RA-receptor com-
plexes directly and indirectly regulate gene transcription. Retinoic
acid receptors and RXRs are related to the steroid/thyroid hormone
superfamily of receptors that primarily function as ligand-inducible
transcription factors [12]. A vast number of gene promoters contain
RAR elements (RAREs) and RXR elements (RXREs) that provide
the means for nuclear receptor complexes to transcriptionally regulate
the downstream gene.
hTERT is one example of a gene that has been shown to be regu-
lated by RAs but lacks both an RARE and a RXRE. The hTERT
promoter contains an estrogen response element and a variety of
binding sites for both activating and inhibiting transcription fac-
tors, and it is the direct effect of RAs on these regulating pro-
teins that allows RAs to indirectly affect hTERT gene expression
[13]. Retinoid X receptors such as Targretin have been shown to
have a lower toxicity than retinoid agonists for RARs and thus
are the primary form of synthetic retinoid currently being investi-
gated for treatment or chemoprevention in many cancer cell lines.
9cUAB30 is a synthetic analog of 9-cis RA, but unlike 9-cis RA,
is an RXR-selective retinoid [14]. This novel retinoid (Figure 1)
has shown great potential as a chemopreventive/treatment agent
in breast cancer differentiation therapy and is far less toxic than
ATRA [15]. In mice, topical treatment with high doses of 9cUAB30
has been demonstrated to inhibit formation of papillomas induced
by dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol 13-
acetate by 54% [16]. It has also been shown to be orally active
in the prevention of N -methyl-N -nitrosourea–induced mammary
cancers in rats without resulting in signs of toxicity [16]. Additional
studies on 9cUAB30 have demonstrated that this agent reduces cel-
lular proliferation in mammary cancer [17]. This retinoid is currently
in phase I clinical trials for pharmacology and toxicology. In the cur-
rent study, the potential of 9cUAB30 to induce differentiation and
inhibit telomerase in human leukemia HL60 cells was assessed be-
cause its mechanisms and efficacy have not yet been evaluated in
leukemia cells.
Materials and Methods
Cell Culture and Proliferation Assessment
HL60 cells (American Type Culture Collection, Manassas, VA)
were cultured in 5% CO2 at 37°C in Iscove’s medium supplemented
with 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT),
1% antibiotic solution: amphotericin B, penicillin, and streptomycin
(Gibco, Carlsbad, CA), and 1% L-glutamine. HL60 cells were seeded
at 3 × 106 cells per 25-cm2 culture flask and were exposed to 5 μM
9cUAB30. This dose was determined through dose-response analyses
(data not shown).
Assessment of Differentiation
Cellular differentiation was determined using fluorescence-activated
cell-sorting (FACS) analyses of CDllb expression, a cell surface protein
of granulocytes. Cells (1 × 106) were washed with cold phosphate-
buffered solution (PBS) and incubated with 2 μg of fluorochrome-
conjugated monoclonal antibody fluorescein isiothiocyanate against
human CD11b antigen (Sigma, St. Louis, MO). After antibody in-
cubation, the cells were washed with PBS containing 1% bovine
serum albumin and 0.1% NaN3, then fixed with 2% paraformal-
dehyde. The cells were analyzed on a Becton Dickinson (San Jose,
CA) FACScalibur flow cytometer with CellQuest software.
Assessment of hTERT Expression
Genomic RNA was purified from thawed cells using the RNeasy
Minikit (Qiagen Sciences, Gaithersburg, MD). Approximately 2 μg
of RNA was reverse-transcribed using the SuperScript Preamplifica-
tion system (Invitrogen, Carlsbad, CA). From this reaction, 1 μl was
used as the template for polymerase chain reaction (PCR) using a
primer set specific for a 216-bp region of the hTERT gene [18] as
well as a 330-bp glyceraldehyde-3-phosphate dehydrogenase amplicon
as the internal control. The PCR products were resolved on a 2%
agarose gel, stained with ethidium bromide (0.5 μg/ml), and visualized
under UV light.
Assessment of Telomerase Activity
The telomeric repeat amplification protocol (TRAP) assay was
performed with the TRAPeze XL kit (Millipore, Temecula, CA)
as previously [19]. Samples underwent PCR amplification (94°C
for 30 seconds, 59°C for 30 seconds, and 72°C for 1 minute) for
36 cycles. The PCR product was visualized on a 10% polyacrylamide
nondenaturing gel stained with SYBR Green (Molecular Probes,
Eugene, OR) and analyzed with Kodak Digital Science software
(Kodak, New Haven, CT).
Analysis of Apoptosis
The degree of apoptosis was measured using the ApopTag Plus
Peroxidase In Situ Apoptosis Detection kit (Chemicon International,
Temecula, CA). Briefly, the harvested HL60 cells were fixed in 1%
paraformaldehyde, quenched with endogenous peroxidase, treated
with anti–digoxigenin peroxidase conjugate, and stained with methyl
green dye. Cells undergoing apoptosis stained brown, whereas non-
apoptotic cells stained green.
Apoptosis was also determined using FACS analyses. According to
the protocol of Vibrant Apoptosis Detection Kit (Invitrogen), 1 mil-
lion cells were washed with cold PBS, and incubated with Alexa488
Figure 1. Structure of 9cUAB30. 9cUAB30 is a synthetic retinoid
related to 9-cis retinoic acid.
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and with propidium iodide. The cells were analyzed on a Becton
Dickinson FACScalibur flow cytometer with CellQuest software.
Results
Decrease in Proliferation and Induction of Differentiation
HL60 cells treated with 5 μM 9cUAB30 (optimal dose deter-
mined by dose-response analysis; data not shown) took on morpho-
logic characteristics of granulocytes, becoming larger and more
internally complex. Clumping was apparent by day 6 and was the
dominant cell distribution by day 12 (Figure 2A). An increase in cells
exhibiting characteristic apoptotic features was observed including
chromatin condensation, nuclear fragmentation, cell shrinkage, and
the presence of apoptotic bodies (data not shown). After peaking at
day 6, the proliferation of the treated cells gradually declined during
the remainder of the treatment period, whereas the control cells
grew exponentially throughout the treatment period (Figure 2B).
The viability of 5 μM 9cUAB30-treated cells decreased to 65.6%
on day 12 (Figure 2C ). In addition to morphologic changes associ-
ated with differentiation, the expression of CD11b increased from
2.3% for controls to 59.5% for treated cells on day 12 (Figure 2D).
Figure 2. Effects of 5 μM 9cUAB30 on HL60 cellular morphology. (A) Original magnification, ×200. Cell photographs were obtained using
a Nikon CoolPix digital camera. (B) Effects of 5 μM 9cUAB30 on proliferation of HL60 cells. Cells were cultured for 0, 3, 6, 9, and 12 days
and counted on a hemacytometer. The mean values of cell counts in triplicate were plotted. Bars, SEM. (C) Changes in cell viability
determined by ratio of live to total cells; (D) Assessment of differentiation after 5 μM 9cUAB30 treatment of HL60 cells. Fluorescence-
activated cell-sorting analyses of HL60 after incubation with fluorochrome conjugates of monoclonal antibody against human CD11b
antigen. CD11b served as a marker of granulocyte differentiation. The values indicate the percentage of CD11b-positive cells.
Figure 3. (A) Effects of 5 μM 9cUAB30 on hTERT mRNA expression
determined by reverse transcription–polymerase chain reaction. (B)
Effects of 5 μM 9cUAB30 on telomerase activity by TRAP assay.
The band of 56-bp served as the internal control for the PCR.
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Inhibition of hTERT Gene Expression and
Telomerase Activity
hTERT expression was down-regulated after day 6 of 5 μM 9cUAB30
treatment of HL60 cells, whereas glyceraldehyde-3-phosphate de-
hydrogenase expression remained constant (Figure 3A). Although
the first 3 days of 9cUAB30 treatment of HL60 cells resulted in
no reduction of hTERT expression, by 6 days of treatment, hTERT
gene expression was attenuated, and by 9 days of treatment with
9cUAB30, it was not detectable. The effect of 9cUAB30 on telome-
rase activity was examined using the TRAP assay method [19]. The
amount of telomerase activity of cells treated with 5 μM 9cUAB30
was similar to the untreated controls on day 3 and only slightly
decreased by day 6 due to the 24-hour half-life of the telomerase
enzyme after mRNA attenuation. There was a sharp decline in telo-
merase activity in response to 9cUAB30 by days 9 and 12. This
loss of band intensity is indicative of a loss of telomerase activity
(Figure 3B).
Induction of Apoptosis
Figure 4A depicts the morphology of HL60 cells treated with
5 μM 9cUAB30 after incubation with anti–digoxigenin peroxi-
dase conjugate and stained with methyl green dye according to the
ApopTag Apoptosis Assay protocol. The cells undergoing apoptosis
stain brown, whereas the nonapoptotic cells stain green (Figure 4,
A–D). The untreated control cells displayed little or no apoptosis
(∼1%; Figure 4, A and E ). In the first 6 days of treatment, a gradual
increase in the number of apoptotic cells occurred. By day 9, how-
ever, there is a considerable amount of apoptosis, and this increased
through day 12. The greatest number of apoptotic HL60 cells was
seen on day 12 (26.2%; Figure 4E ).
Figure 4. Analysis of apoptosis determined by the ApopTag Apoptosis assay for 5 μM 9cUAB30. Brown cells are apoptotic and green
cells are not apoptotic. (A) No RA; (B) day 6 of 5 μM 9cUAB30; (C) day 9 of 5 μM 9cUAB30; (D) day 12 of 5 μM 9cUAB30. (E) Summary
graph of apoptosis determined by ApopTag Apoptosis assay. Percentage of apoptosis for HL60 cells treated with 5 μM 9cUAB30.
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Discussion
In this study, we have shown that 9cUAB30, the novel retinoid
that is much less toxic than ATRA [16], down-regulated telomerase
activity in HL60 leukemia cells and this loss of telomerase activity
resulted in an induction of apoptosis in more than 25% of these cells.
A safe and effective means of telomerase inhibition is a much sought-
after therapy for cancer [20]. Because telomerase is down-regulated
during embryonic development as stem cells differentiate into nor-
mal somatic cells and is up-regulated in up to 95% of leukemias,
it serves as an excellent target for antileukemia therapies. 9cUAB30
RA is an RXR-selective synthetic analogue of 9-cis RA [14,15] and,
as such, should be less toxic than RAR-selective retinoids such as
ATRA or pan-agonists of RARs and RXRs such as 9-cis RA.
Many genes have RAREs and RXREs in their promoter. Other
genes may be downstream targets of the retinoids. Although hTERT
has not been found to have an RARE or an RXRE, hTERT suppres-
sion may be a downstream effect of retinoid receptor activation.
Downstream targets of RA that could facilitate hTERT suppression
involve the c-Myc/Max heterodimer, p53, DNA methyltransferases,
and histone deacetylases.
Like ATRA, 9cUAB30 has an antiproliferative effect on HL60
cells (Figure 2). The changes in cellular morphology shown in Fig-
ure 2 reveal a progression toward a generally differentiated morphol-
ogy. 9cUAB30 displayed an ability to induce apoptosis and inhibit
telomerase activity comparable to that of ATRA (data not shown),
whereas its ability to induce differentiation as measured by CD11b
expression was one third less than ATRA (Figure 4 and data not
shown). This finding is in agreement with those of previous studies
[21,22] demonstrating that the ability of a retinoid to induce differ-
entiation in NB4 leukemia cells correlates with activation of RARα.
9cUAB30 binds and activates only RXR retinoid receptors, unlike
9-cis RA, which is a pan-agonist [16,17]. 9cUAB30 treatment inhib-
ited hTERT expression before either a decrease in proliferative ability
or terminal differentiation, suggesting that hTERT inhibition may
be mediated by a different pathway other than induction of differ-
entiation. The effects demonstrated by 9cUAB30 on apoptosis and
telomerase activity may be induced through RXR homodimers or
RAR-RXR heterodimers activated in an RXR-selective manner [23].
In summary, hTERT up-regulation has long been known as a key
element in tumorigenesis, vital to the immortality of cancer cells. Here
we have shown that 9cUAB30 treatment leads to down-regulation of
hTERT expression, decrease in telomerase activity, and induction of ap-
optosis of HL60 human leukemia cells. These findings strongly support
9cUAB30 as a treatment/chemopreventive agent. Future studies will
be needed to elucidate the exact mechanisms responsible for the role
9cUAB30 plays in hTERT gene expression. Introduction of 9cUAB30
into breast cancer cells has been shown to cause a down-regulation of
DNA methyltransferase expression, and it is this loss of DNA methyla-
tion activity that may cause a decrease in hTERT expression [24]. It is
well known that hTERT expression is regulated by both genetic and
epigenetic mechanisms, and this fact may suggest that 9cUAB30 asserts
it anticancer effects through epigenetic mechanisms.
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